Want to see HK:2142 full AI Analyst Report?
2142 Stock Chart & Stats
HK$12.08
HK$0.18(8.04%)
At close: 4:00 PM EST
HK$12.08
HK$0.18(8.04%)
Day’s Range― - ―
52-Week RangeHK$9.12 - HK$17.98
Previous CloseN/A
Volume9.30M
Average Volume (3M)8.63M
Market Cap
HK$10.83B
Enterprise ValueHK$884.55M
Total Cash (Recent Filing)HK$401.90M
Total Debt (Recent Filing)HK$81.77M
Price to Earnings (P/E)22.3
Beta1.24
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding900,175,700
10 Day Avg. Volume6,681,047
30 Day Avg. Volume8,634,233
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.37
Price to Sales (P/S)7.82
P/FCF Ratio17.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.13
Revenue Forecast (FY)HK$237.92M
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundThe sharp margin expansion and earnings rebound in 2025 materially improve the company's capacity to generate cash and deliver returns. Sustained very high gross and net margins would support durable profitability, permit higher reinvestment in R&D or commercialization, and enhance long-term capital allocation flexibility.
Improved LeverageThe marked reduction in leverage alongside a larger equity base strengthens balance-sheet resilience and financial flexibility. Lower debt ratios and improved ROE reduce solvency and refinancing risk, giving management more headroom to invest in growth or weather volatility without immediate funding pressure.
Positive Free Cash FlowConsistent positive operating and free cash flow in 2025 materially increases the firm's ability to self-fund operations and strategic initiatives. Reliable FCF improves liquidity, lowers dependence on external financing for capex or M&A, and, if sustained, supports value-accretive reinvestment.
Bears Say
Multi-year VolatilityHistoric multi-year swings in revenue, margins, and cash flow reduce confidence that the 2025 improvements will persist. Such volatility increases forecasting uncertainty, complicates investment decisions, and raises the probability that one-time factors or timing differences contributed to the rebound rather than sustained structural gains.
Uneven Cash ConversionPeriods of significant cash burn and negative cash flow erode liquidity cushions and elevate the risk of needing external funding during downturns. Inconsistent cash conversion makes free cash available for growth or debt reduction unpredictable, limiting the firm's ability to plan multi-year investments confidently.
Inconsistent Revenue TrendA sharp 2025 revenue surge following a prior year decline signals inconsistency in demand or recognition timing. Irregular top-line growth undermines scale economics and raises the risk that margin and earnings gains are cyclical or concentrated, challenging the predictability of sustainable growth over the next several quarters.
HBM Holdings Ltd. News
2142 FAQ
What was HBM Holdings Ltd.’s price range in the past 12 months?
HBM Holdings Ltd. lowest stock price was HK$9.12 and its highest was HK$17.98 in the past 12 months.
What is HBM Holdings Ltd.’s market cap?
HBM Holdings Ltd.’s market cap is HK$10.83B.
When is HBM Holdings Ltd.’s upcoming earnings report date?
HBM Holdings Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 26 days.
How were HBM Holdings Ltd.’s earnings last quarter?
HBM Holdings Ltd. released its earnings results on Mar 30, 2026. The company reported HK$0.183 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.183.
Is HBM Holdings Ltd. overvalued?
According to Wall Street analysts HBM Holdings Ltd.’s price is currently Overvalued.
Does HBM Holdings Ltd. pay dividends?
HBM Holdings Ltd. does not currently pay dividends.
What is HBM Holdings Ltd.’s EPS estimate?
HBM Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HBM Holdings Ltd. have?
HBM Holdings Ltd. has 900,175,700 shares outstanding.
What happened to HBM Holdings Ltd.’s price movement after its last earnings report?
HBM Holdings Ltd. reported an EPS of HK$0.183 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.028%.
Which hedge fund is a major shareholder of HBM Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2142
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HBM Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
928.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
133.13%
Trailing 12-Months
Company Description
HBM Holdings Ltd.
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while Tanfanercept (HBM9036) is under development to address moderate to severe dry eye disease. For oncology, HBM Holdings is advancing various therapies, such as HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody. Additional cancer candidates in their portfolio include HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and a suite of treatments—HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022—geared towards solid tumors. Furthermore, HBM9022 is being developed to treat SARS-COV-2. Operating globally, HBM Holdings has a presence in Mainland China, the United States, Europe, and other international markets. The company also fosters strategic partnerships for antibody-drug conjugate (ADC) projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was founded in 2016 and is based in Shanghai, People's Republic of China.
Technical Analysis
Alphamab Oncology
―
Everest Medicines Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
CStone Pharmaceuticals
―